Core Viewpoint - The stock of Sino Medical Technology Co., Ltd. has experienced significant abnormal fluctuations, with a cumulative price increase of 100% over five consecutive trading days, prompting the company to issue a notice regarding the situation [1][4][5]. Stock Trading Abnormalities - The stock price of Sino Medical increased by 30% over three consecutive trading days from August 11 to August 13, 2025 [1][4]. - The closing price on August 13, 2025, was 29.50 yuan per share, with the recent price increase surpassing that of most peers in the industry and the Shanghai Composite Index [2][7]. - The rolling price-to-earnings (P/E) ratio of the company is 1701.41, significantly deviating from the industry average P/E ratio of 33.59 [2][7]. Company Disclosures - The company has disclosed that it received conditional approval from the FDA for a new drug-eluting stent system on July 22, 2025, and a breakthrough medical device designation for its COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter on August 7, 2025 [1][3][5]. - The breakthrough designation by the FDA provides priority review and support for product development and clinical trials, although it does not guarantee subsequent approval for market entry [3][8]. Shareholder and Control Information - The company confirmed that there are no undisclosed significant matters affecting stock trading, including major asset restructuring or debt restructuring, as of the announcement date [2][5][6]. - The company’s major shareholders and actual controllers have not reported any significant events that could influence stock trading [2][5].

Core Viewpoint - The stock of Sino Medical Technology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price drop of 30% over two consecutive trading days on August 7 and August 8, 2025 [1][2]. Group 1: Abnormal Trading Fluctuation - The stock trading of Sino Medical on August 7 and August 8, 2025, showed a cumulative closing price drop of 30%, qualifying as an abnormal trading fluctuation according to the Shanghai Stock Exchange regulations [1][2]. - The company conducted a self-examination and confirmed that no significant media reports or market rumors could impact the stock price, and there are no undisclosed major information affecting the trading price [1][3]. Group 2: Company Disclosures - The company previously disclosed that its new drug-eluting stent system received conditional approval from the FDA on July 22, 2025, and a subsidiary's product received breakthrough medical device certification from the FDA on August 7, 2025 [1][3]. - The company has not identified any need to correct or supplement previously disclosed information, and its normal production and operation status remains unaffected [1][3][4]. Group 3: Shareholder and Control Information - The company confirmed that its controlling shareholders and actual controllers do not have any major matters that could influence the abnormal trading fluctuation, including significant asset restructuring or debt restructuring [2][3].

Core Viewpoint - The stock market on August 7 showed significant activity with several companies experiencing notable trading volumes and consecutive price increases, indicating strong investor interest and potential growth opportunities in specific sectors [1]. Group 1: Trading Activity - On August 7, the top three companies by closing limit order volume were Jihua Group with 418,600 hands, Tianyu Digital Science with 396,600 hands, and Jishi Media with 323,700 hands [1]. - A total of 22 stocks had limit order funds exceeding 100 million yuan, with Tianyu Digital Science, Dongxin Technology, Sainuo Medical, Beiwai Technology, Huasheng Tiancheng, and Jihua Group each having over 200 million yuan in limit order funds [1]. Group 2: Consecutive Price Increases - *ST Dongjing and *ST Yushun achieved five consecutive limit increases, while Beiwai Technology, Furi Electronics, and Guoji Precision Engineering recorded four consecutive increases [1]. - ST Chenming, Hongtong Gas, Rihai Intelligent, Zhongxin Fluorine Materials, and Huaguang Huaneng each achieved three consecutive limit increases [1]. Group 3: Individual Company Highlights - Tianyu Digital Science closed at 7.45 yuan with a turnover rate of 22.21% and a limit order volume of 396,600 hands, driven by advancements in physical AI and embodied intelligence [2]. - Jihua Group closed at 4.80 yuan with a turnover rate of 9.66% and a limit order volume of 418,600 hands, supported by military supplies and brain-machine interface technologies [2]. - Sainuo Medical closed at 17.03 yuan with a turnover rate of 2.10% and a limit order volume of 135,500 hands, benefiting from breakthrough FDA certifications and expected mid-year profit increases [2].